Blue Trust Inc’s Anika Therapeutics ANIK Stock Holding History

Blue Trust Inc’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24	Closed	-$361	–	2451
2025 Q1	$361	Buy	+24	New	+$399	﹤0.01%	2386

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

Blue Trust Inc's ANIK Position: Q2 2025 in Review

Blue Trust Inc sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 24 shares — an estimated $361 sold.

Blue Trust Inc first reported a position in ANIK in Q1 2025 and held it in 1 quarter. The position peaked at $361 in Q1 2025. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

Blue Trust Inc reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
Blue Trust Inc sold 24 Anika Therapeutics shares in Q2 2025, an estimated $361.
Blue Trust Inc first reported a position in Anika Therapeutics in Q1 2025 and held it in 1 quarter.
Blue Trust Inc's Anika Therapeutics position peaked at $361 in Q1 2025.
103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on Blue Trust Inc's 13F filing for Q2 2025, filed 24 Jul 2025.